Bortezomib in relapsed or refractory myeloma patients

被引：0
|
作者：
Leonetti Crescenzi, S. [1 ]
Piccioni, A. L. [1 ]
Bagnato, A. [1 ]
机构：
[1] Osped Sandro Pertini, UOC Ematol, ASL Roma B, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2007年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：208 / 208
页数：1
相关论文
共 50 条
  • [1] Bortezomib in Relapsed/Refractory Multiple Myeloma
    Shen, Z.
    Wang, L.
    Yan, H.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S62 - S62
  • [2] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [3] A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma
    Lee, KW
    Yun, T
    Song, EK
    Na, II
    Shin, H
    Bang, SM
    Lee, JH
    Lee, ST
    Kim, JH
    Yoon, SS
    Lee, JS
    Park, S
    Kim, BK
    Kim, NK
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2005, 20 (04) : 598 - 602
  • [4] Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Richardson, Paul G.
    Badros, Ashraf Z.
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 428 - 437
  • [5] Carfilozomib versus bortezomib for relapsed or refractory myeloma
    Vogl, Steven E.
    LANCET ONCOLOGY, 2016, 17 (04): : E125 - E126
  • [6] A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
    Richardson, Paul G.
    Xie, Wanling
    Jagannath, Sundar
    Jakubowiak, Andrzej
    Lonial, Sagar
    Raje, Noopur S.
    Alsina, Melissa
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Mazumder, Amitabha
    Vesole, David H.
    Kaufman, Jonathan L.
    Colson, Kathleen
    McKenney, Mary
    Lunde, Laura E.
    Feather, John
    Maglio, Michelle E.
    Warren, Diane
    Francis, Dixil
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Mitsiades, Constantine S.
    Weller, Edie
    Anderson, Kenneth C.
    BLOOD, 2014, 123 (10) : 1461 - 1469
  • [7] Bortezomib in relapsed/refractory myeloma patients: A single-center experience
    Grasso, M.
    Tavera, S.
    Bonferroni, M.
    Calvi, R.
    Rapezzi, D.
    Gallamini, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 149 - 150
  • [8] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    Kovalchuk, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 616 - 616
  • [9] ANTITUMOR ACTIVITY OF BORTEZOMIB RETREATMENT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS
    Skvortsova, N.
    Pospelova, T.
    Nechunaeva, I.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 590 - 590
  • [10] Bortezomib in relapsed or refractory multiple myeloma:: results in a cohort of 39 patients
    Canovas Fernandez, A.
    Alonso Alonso, J. J.
    Barreiro Garcia, J. G.
    Aguirre Errasti, C.
    REVISTA CLINICA ESPANOLA, 2008, 208 (04): : 187 - 192
12345